Researchers at the University of Cambridge have developed what they describe as a “fundamentally new” type of vaccine using artificial intelligence (AI). Scientists say it is the first time that the key component of a vaccine has been designed entirely by AI and then tested in human volunteers.
The vaccine is designed to provide protection against a wide range of coronaviruses, including current Covid-19 variants as well as related viruses that could potentially trigger future pandemics. Researchers hope the technology will help scientists stay ahead of rapidly mutating viruses instead of constantly updating vaccines after new variants emerge.
To create the vaccine, scientists used genetic data from multiple coronaviruses collected through surveillance programs. An AI system analyzed the data and designed a “super-antigen” capable of training the immune system to recognize and fight a broad family of viruses.
The first human trial involved 39 participants and primarily focused on evaluating the vaccine’s safety. Researchers reported that the vaccine generated a modest immune response, while larger studies involving around 200 participants are expected to provide more information about its effectiveness.
Scientists involved in the project believe AI could significantly accelerate vaccine development and improve global preparedness against future outbreaks. The research team is already exploring similar AI-designed vaccines targeting influenza, bird flu (H5N1), and Ebola-related viruses.
Experts say the technology represents a major step forward in vaccine science and could eventually lead to universal vaccines that offer broader and longer-lasting protection against evolving infectious diseases.
